Publications

• Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract.
  Clin Lymphoma Myeloma Leuk
  04/08/2025 Authors: Scott SA; Roberts DL; Gupta VA; Joseph NS; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK; Kaufman JL
• Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
  Blood Cancer J Volume: 14 Page(s): 159
  09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S
• Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
  Bone Marrow Transplant Volume: 59 Page(s): 196 - 202
  02/01/2024 Authors: Maze D; Arcasoy MO; Henrie R; Cerquozzi S; Kamble R; Al-Hadidi S; Yacoub A; Singh AK; Elsawy M; Sirhan S
• Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
  Br J Haematol Volume: 204 Page(s): 206 - 220
  01/01/2024 Authors: de Castro FA; Mehdipour P; Chakravarthy A; Ettayebi I; Loo Yau H; Medina TS; Marhon SA; de Almeida FC; Bianco TM; Arruda AGF
• Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
  Blood Cancer J Volume: 13 Page(s): 191
  12/20/2023 Authors: Scott SA; Marin EM; Maples KT; Joseph NS; Hofmeister CC; Gupta VA; Dhodapkar MV; Kaufman JL; Lonial S; Nooka AK
• Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
  Cancer Res Commun Volume: 3 Page(s): 2497 - 2509
  12/08/2023 Authors: Juarez D; Buono R; Matulis SM; Gupta VA; Duong M; Yudiono J; Paul M; Mallya S; Diep G; Hsin P
• MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Nave Myelofibrosis.
  J Clin Oncol Volume: 41 Page(s): 4993 - 5004
  11/10/2023 Authors: Mascarenhas J; Kremyanskaya M; Patriarca A; Palandri F; Devos T; Passamonti F; Rampal RK; Mead AJ; Hobbs G; Scandura JM
• Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
  Blood Adv Volume: 7 Page(s): 5835 - 5842
  10/10/2023 Authors: Oh ST; Mesa RA; Harrison CN; Bose P; Gerds AT; Gupta V; Scott BL; Kiladjian J-J; Lucchesi A; Kong T
• Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
  Blood Adv Volume: 7 Page(s): 5421 - 5432
  09/26/2023 Authors: Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian J-J; Vannucchi AM; Verstovsek S; Colak G; Dey D
• Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study.
  Blood Adv Volume: 7 Page(s): 5014 - 5026
  09/12/2023 Authors: Bankar A; Chan WC; Liu N; Cheung M; Alibhai S; Gupta V
• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
  Lancet Haematol Volume: 10 Page(s): e735 - e746
  09/01/2023 Authors: Gerds AT; Verstovsek S; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC
• A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.
  Blood Adv Volume: 7 Page(s): 3993 - 4002
  08/08/2023 Authors: Tamari R; McLornan DP; Ahn KW; Estrada-Merly N; Hernndez-Boluda JC; Giralt S; Palmer J; Gale RP; DeFilipp Z; Marks DI
• Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
  J Clin Invest Volume: 133
  08/01/2023 Authors: Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S
• Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
  Haematologica Volume: 108 Page(s): 1900 - 1908
  07/01/2023 Authors: Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A
• Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.
  Eur J Haematol Volume: 110 Page(s): 618 - 625
  06/01/2023 Authors: Vasudevan Nampoothiri R; Tang K; Schuh A; Lam W; Maze D; Michelis FV; Chan S; Gupta V; Kim D; Kumar R
• Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
  Br J Haematol Volume: 201 Page(s): 645 - 652
  05/01/2023 Authors: Chen R; Atenafu EG; Seki J; Liu X; Chan S; Gupta V; Maze D; Shuh AC; Minden MD; Yee K
• Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor.
  Am J Hematol Volume: 98 Page(s): E127 - E129
  05/01/2023 Authors: England JT; Atenafu EG; Kennedy JA; Goraya B; Cheung V; Nye T; Gauthier K; Davidson MB; Bankar A; Sibai H
• Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
  Cancer Med Volume: 12 Page(s): 10612 - 10624
  05/01/2023 Authors: Mesa RA; Hudgens S; Floden L; Harrison CN; Palmer J; Gupta V; McLornan DP; McMullin MF; Kiladjian J-J; Foltz L
• Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.
  Nat Cancer Volume: 4 Page(s): 754 - 773
  05/01/2023 Authors: de Matos Simoes R; Shirasaki R; Downey-Kopyscinski SL; Matthews GM; Barwick BG; Gupta VA; Dupr-Richer D; Yamano S; Hu Y; Sheffer M
• Screening for signs of portal hypertension by esophagogastroduodenoscopy in patients with BCR-ABL negative myeloproliferative neoplasms.
  Am J Hematol Volume: 98 Page(s): E88 - E90
  04/01/2023 Authors: Davidson M; Wong F; Atri M; Sibai H; Maze D; Cheung V; Callum J; Atenafu EG; Gupta V
• Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
  Blood Cancer J Volume: 13 Page(s): 29
  02/20/2023 Authors: Maples KT; Hall KH; Joseph NS; Hofmeister CC; Gupta V; Dhodapkar MV; Kaufman JL; Nooka AK; Lonial S
• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
  Lancet Volume: 401 Page(s): 269 - 280
  01/28/2023 Authors: Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC
• Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia.
  Acta Haematol Volume: 146 Page(s): 366 - 372
  01/01/2023 Authors: Hershenfeld SA; Atenafu EG; Chan S; Gupta V; Maze D; Schuh A; Sibai H; Yee K; Schimmer AD
• Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinion.
  Am J Hematol Volume: 97 Page(s): E466 - E469
  12/01/2022 Authors: Szuber N; Toliopoulos P; Busque L; Cerquozzi S; Foltz L; Gupta V; Tefferi A; Vannucchi AM; Hillis C; Leber B
• Implementation of a Routine Screening Program for Latent Tuberculosis Infection among Patients with Acute Leukemia at a Canadian Cancer Center.
  Curr Oncol Volume: 29 Page(s): 9325 - 9334
  11/29/2022 Authors: Taha R; Kothari S; Foroutan F; Gitman M; Gupta V; Nguyen T; Rotstein C
• Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis.
  Am J Hematol Volume: 97 Page(s): 1464 - 1477
  11/01/2022 Authors: Perram J; Ross DM; McLornan D; Gowin K; Krger N; Gupta V; Lewis C; Gagelmann N; Hamad N
• Hospital-onset bacteremia and fungemia: An evaluation of predictors and feasibility of benchmarking comparing two risk-adjusted models among 267 hospitals.
  Infect Control Hosp Epidemiol Volume: 43 Page(s): 1317 - 1325
  10/01/2022 Authors: Yu KC; Ye G; Edwards JR; Gupta V; Benin AL; Ai C; Dantes R
• MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S336
  10/01/2022 Authors: Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian J-J; Vannucchi A; Verstovsek S; Colak G; Dey D
• MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Nae or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S335 - S336
  10/01/2022 Authors: Mascarenhas J; Kremyanskaya M; Patriarca A; Harrison C; Bose P; Rampal RK; Palandri F; Devos T; Passamonti F; Hobbs G
• MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S339 - S340
  10/01/2022 Authors: Mesa R; Gerds A; Vannucchi A; Al-Ali HK; Lavie D; Kuykendall A; Grosicki S; Iurlo A; Goh YT; Lazaroiu M
• MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM].
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S340
  10/01/2022 Authors: Gerds A; Verstovsek S; Vannucchi A; Al-Ali HK; Lavie D; Kuykendall A; Grosicki S; Iurlo A; Goh YT; Lazaroiu M
• AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S246 - S247
  10/01/2022 Authors: Pammaraju N; Kantarjian H; Sweet K; Wang ES; Lane AA; Ali H; Stein AS; Yacoub A; Rizzieri D; Vasu S
• MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S327
  10/01/2022 Authors: Oh S; Mesa R; Harrison C; Bose P; Gerds A; Gupta V; Swami A; Tyavanagimatt S; Buckley S; Roman-Torres K
• Fedratinib: a pharmacotherapeutic option for JAK-inhibitor nave and exposed patients with myelofibrosis.
  Expert Opin Pharmacother Volume: 23 Page(s): 1677 - 1686
  10/01/2022 Authors: England JT; Gupta V
• Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.
  Sci Adv Volume: 8 Page(s): eabq5575
  09/30/2022 Authors: Sharma A; Nair R; Achreja A; Mittal A; Gupta P; Balakrishnan K; Edgar CL; Animasahun O; Dwivedi B; Barwick BG
• Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis.
  Nat Commun Volume: 13 Page(s): 5284
  09/08/2022 Authors: Brown DW; Zhou W; Wang Y; Jones K; Luo W; Dagnall C; Teshome K; Klein A; Zhang T; Lin S-H
• Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
  Br J Haematol Volume: 198 Page(s): 1065 - 1068
  09/01/2022 Authors: Kosiorek HE; Scherber RM; Geyer HL; Verstovsek S; Langlais BT; Mazza GL; Gotlib J; Gupta V; Padrnos LJ; Palmer JM
• Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
  Leukemia Volume: 36 Page(s): 2261 - 2268
  09/01/2022 Authors: Mesa R; Harrison C; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian J-J
• Phase III MANIFEST-2: pelabresib+ ruxolitinib vs placebo+ ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
  Future Oncol Volume: 18 Page(s): 2987 - 2997
  09/01/2022 Authors: Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian J-J; Mesa R; Kuykendall AT; Vannucchi AM
• Venetoclax ex vivo functional profiling predicts improved progression-free survival.
  Blood Cancer J Volume: 12 Page(s): 115
  08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT
• Momelotinib reduces transfusion requirements in patients with myelofibrosis.
  Leuk Lymphoma Volume: 63 Page(s): 1718 - 1722
  07/01/2022 Authors: Mesa R; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian J-J; Lech-Maranda E
• Defining disease modification in myelofibrosis in the era of targeted therapy.
  Cancer Volume: 128 Page(s): 2420 - 2432
  07/01/2022 Authors: Pemmaraju N; Verstovsek S; Mesa R; Gupta V; Garcia JS; Scandura JM; Oh ST; Passamonti F; Dhner K; Mead AJ
• Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.
  Leukemia Volume: 36 Page(s): 1689 - 1692
  06/01/2022 Authors: England JT; McNamara CJ; Kennedy JA; Capo-Chichi J-M; Huang J; Arruda A; Nye T; Cheung V; Claudio JO; Maze D
• It takes T to tango: immunotherapy in MM.
  Blood Volume: 139 Page(s): 1259 - 1260
  03/03/2022 Authors: Gupta VA; Dhodapkar MV
• Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study.
  Leukemia Volume: 36 Page(s): 856 - 864
  03/01/2022 Authors: Kunte S; Rybicki L; Viswabandya A; Tamari R; Bashey A; Keyzner A; Iqbal M; Grunwald MR; Dholaria B; Elmariah H
• Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux.
  Commun Biol Volume: 5 Page(s): 132
  02/15/2022 Authors: Dotan I; Yang J; Ikeda J; Roth Z; Pollock-Tahiri E; Desai H; Sivasubramaniyam T; Rehal S; Rapps J; Li YZ
• Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
  Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
  02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT
• Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?
  Hematology Am Soc Hematol Educ Program Volume: 2021 Page(s): 453 - 462
  12/10/2021 Authors: England J; Gupta V
• Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis.
  Eur J Haematol Volume: 107 Page(s): 517 - 528
  11/01/2021 Authors: Cyriac S; Prem S; Salas MQ; Chen S; Al-Shaibani Z; Lam W; Law A; Gupta V; Michelis FV; Kim DDH
• Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
  Blood Cancer Discov Volume: 2 Page(s): 600 - 615
  11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC
• Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
  Hematol Oncol Volume: 39 Page(s): 558 - 566
  10/01/2021 Authors: Passamonti F; Gupta V; Martino B; Foltz L; Zaritskey A; Al-Ali HK; Tavares R; Maffioli M; Raanani P; Giraldo P
• Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.
  Leukemia Volume: 35 Page(s): 2989 - 2993
  10/01/2021 Authors: Barbui T; De Stefano V; Carobbio A; Iurlo A; Alvarez-Larran A; Cuevas B; Ferrer Marn F; Vannucchi AM; Palandri F; Harrison C
• Critical illness in patients with hematologic malignancy: a population-based cohort study.
  Intensive Care Med Volume: 47 Page(s): 1104 - 1114
  10/01/2021 Authors: Ferreyro BL; Scales DC; Wunsch H; Cheung MC; Gupta V; Saskin R; Thyagu S; Munshi L
• Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study.
  Br J Haematol Volume: 194 Page(s): 557 - 567
  08/01/2021 Authors: Bankar A; Alibhai S; Smith E; Yang D; Malik S; Cheung V; Siddiq N; Claudio J; Arruda A; Tsui H
• Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
  Bone Marrow Transplant Volume: 56 Page(s): 1908 - 1918
  08/01/2021 Authors: Daher-Reyes G; Kim T; Novitzky-Basso I; Kim KH; Smith A; Stockley T; Capochichi J-M; Al-Shaibani Z; Pasic I; Law A
• Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
  Blood Volume: 137 Page(s): 3604 - 3615
  07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT
• Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis.
  Transplant Cell Ther Volume: 27 Page(s): 600.e1 - 600.e8
  07/01/2021 Authors: Smith E; Huang J; Viswabandya A; Maze D; Malik S; Cheung V; Siddiq N; Claudio J; Arruda A; Kennedy J
• Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
  Leuk Lymphoma Volume: 62 Page(s): 1525 - 1527
  06/01/2021 Authors: Garcia-Horton A; Maze D; McNamara CJ; Sibai H; Gupta V; Murphy T
• Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.
  Clin Cancer Res Volume: 27 Page(s): 3178 - 3189
  06/01/2021 Authors: Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC
• Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joining.
  Nat Commun Volume: 12 Page(s): 2455
  04/28/2021 Authors: Feldman T; Bercovich A; Moskovitz Y; Chapal-Ilani N; Mitchell A; Medeiros JJF; Biezuner T; Kaushansky N; Minden MD; Gupta V
• Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
  Leukemia Volume: 35 Page(s): 1197 - 1202
  04/01/2021 Authors: Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T
• MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
  Future Oncol Volume: 17 Page(s): 1449 - 1458
  04/01/2021 Authors: Verstovsek S; Chen C-C; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian J-J; Lazaroiu MC
• Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
  Leuk Lymphoma Volume: 62 Page(s): 918 - 926
  04/01/2021 Authors: Gupta V; Griesshammer M; Martino B; Foltz L; Tavares R; Al-Ali HK; Giraldo P; Guglielmelli P; Lomaia E; Bouard C
• Application of Stem Cell Therapy in Myelofibrosis.
  Hematol Oncol Clin North Am Volume: 35 Page(s): 391 - 407
  04/01/2021 Authors: Davidson MB; Gupta V
• Oncolytic herpes simplex virus infects myeloma cells invitro and invivo.
  Mol Ther Oncolytics Volume: 20 Page(s): 519 - 531
  03/26/2021 Authors: Ghose J; Dona A; Murtadha M; Gunes EG; Caserta E; Yoo JY; Russell L; Jaime-Ramirez AC; Barwick BG; Gupta VA
• Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.
  Blood Adv Volume: 5 Page(s): 975 - 983
  02/23/2021 Authors: Grunwald MR; Zhang M-J; Elmariah H; Johnson MH; St Martin A; Bashey A; Battiwalla M; Bredeson CN; Copelan E; Cutler CS
• Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib.
  Leuk Lymphoma Volume: 62 Page(s): 495 - 497
  02/01/2021 Authors: Garcia-Horton A; Smith E; Maze D; McNamara C; Sibai H; Gupta V
• BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma.
  Blood Lymphat Cancer Volume: 11 Page(s): 11 - 24
  01/01/2021 Authors: Gupta VA; Ackley J; Kaufman JL; Boise LH
• Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
  Haematologica Volume: 106 Page(s): 56 - 63
  01/01/2021 Authors: Puckrin R; Atenafu EG; Claudio JO; Chan S; Gupta V; Maze D; McNamara C; Murphy T; Shuh AC; Yee K
• Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
  Curr Oncol Volume: 28 Page(s): 128 - 137
  12/22/2020 Authors: Chen R; Liu X; Law AD; Kanfar S; Maze D; Chan SM; Gupta V; Yee KW; Minden MD; Schimmer AD
• Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
  Br J Haematol Volume: 191 Page(s): 748 - 754
  12/01/2020 Authors: Sibai H; Chen R; Liu X; Falcone U; Schimmer A; Schuh A; Law A; McNamara C; Maze D; Yee K
• Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase.
  Blood Adv Volume: 4 Page(s): 5562 - 5573
  11/10/2020 Authors: Gupta V; Kennedy JA; Capo-Chichi J-M; Kim S; Hu Z-H; Alyea EP; Popat UR; Sobecks RM; Scott BL; Gerds AT
• Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
  Blood Adv Volume: 4 Page(s): 4748 - 4757
  10/13/2020 Authors: Gupta V; Kim S; Hu Z-H; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn J-Y; Cerny J; Copelan E
• ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
  Blood Adv Volume: 4 Page(s): 4282 - 4291
  09/22/2020 Authors: Oh ST; Talpaz M; Gerds AT; Gupta V; Verstovsek S; Mesa R; Miller CB; Rivera CE; Fleischman AG; Goel S
• Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada.
  Leuk Lymphoma Volume: 61 Page(s): 1908 - 1919
  08/01/2020 Authors: Bankar A; Zhao H; Iqbal J; Coxford R; Cheung MC; Mozessohn L; Earle CC; Gupta V
• Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study.
  Blood Adv Volume: 4 Page(s): 3063 - 3071
  07/14/2020 Authors: Gupta V; Wolleschak D; Hasselbalch H; Vannucchi AM; Koschmieder S; Cervantes F; Li Y; Dong T; Wroclawska M; Bharathy S
• Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.
  JCO Oncol Pract Volume: 16 Page(s): 351 - 359
  07/01/2020 Authors: Gupta V; Cerquozzi S; Foltz L; Hillis C; Devlin R; Elsawy M; Grewal K; Hamm C; McNamara C; Sirhan S
• Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
  Br J Haematol Volume: 189 Page(s): 888 - 903
  06/01/2020 Authors: Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; Garca-Hernndez C; Zaritskey A
• Survival following allogeneic transplant in patients with myelofibrosis.
  Blood Adv Volume: 4 Page(s): 1965 - 1973
  05/12/2020 Authors: Gowin K; Ballen K; Ahn KW; Hu Z-H; Ali H; Arcasoy MO; Devlin R; Coakley M; Gerds AT; Green M
• Investigational non-JAK inhibitors for chronic phase myelofibrosis.
  Expert Opin Investig Drugs Volume: 29 Page(s): 461 - 474
  05/01/2020 Authors: Bankar A; Gupta V
• Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
  J Immunother Cancer Volume: 8
  03/01/2020 Authors: Merino DM; McShane LM; Fabrizio D; Funari V; Chen S-J; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R
• Approaches to Treating Multiple Myeloma, Now and Moving Forward.
  JCO Oncol Pract Volume: 16 Page(s): 15 - 16
  01/01/2020 Authors: Gupta VA; Joseph NS; Nooka AK
• Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
  Blood Cancer J Volume: 9 Page(s): 94
  11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J
• Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis.
  JAMA Netw Open Volume: 2 Page(s): e1912666
  10/02/2019 Authors: Maze D; Kazi S; Gupta V; Malinowski AK; Fazelzad R; Shah PS; Shehata N
• Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
  Blood Adv Volume: 3 Page(s): 2307 - 2311
  08/13/2019 Authors: Murphy T; Zou J; Daher-Reyes GS; Arruda A; Gupta V; McNamara CJ; Minden MD; Schimmer AD; Sibai H; Yee KWL
• Daratumumab in multiple myeloma.
  Cancer Volume: 125 Page(s): 2364 - 2382
  07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
• A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.
  Support Care Cancer Volume: 27 Page(s): 2295 - 2300
  06/01/2019 Authors: Brandwein JM; Seki JT; Atenafu EG; Rostom A; Lutynski A; Rydlewski A; Schimmer AD; Schuh AC; Gupta V; Yee KWL
• Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.
  Biol Blood Marrow Transplant Volume: 25 Page(s): 1158 - 1163
  06/01/2019 Authors: Michelis FV; Hedley DW; Malhotra S; Chow S; Loach D; Gupta V; Kim DD; Kuruvilla J; Lipton JH; Viswabandya A
• Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
  Biol Blood Marrow Transplant Volume: 25 Page(s): 1142 - 1151
  06/01/2019 Authors: Tamari R; Rapaport F; Zhang N; McNamara C; Kuykendall A; Sallman DA; Komrokji R; Arruda A; Najfeld V; Sandy L
• Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
  Leukemia Volume: 33 Page(s): 1291 - 1296
  05/01/2019 Authors: Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL
• Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
  Nat Commun Volume: 10 Page(s): 1911
  04/23/2019 Authors: Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D
• Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
  Cancer Volume: 125 Page(s): 416 - 423
  02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK
• Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns.
  Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): e37 - e42
  01/01/2019 Authors: Habib LA; Kuo KHM; Panzarella T; Gupta V; Trinkaus M
• Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma.
  Front Immunol Volume: 10 Page(s): 1121
  01/01/2019 Authors: Barwick BG; Gupta VA; Vertino PM; Boise LH
• Critical care usage after major gastrointestinal and liver surgery: a prospective, multicentre observational study.
  Br J Anaesth Volume: 122 Page(s): 42 - 50
  01/01/2019 Authors: STARSurg Collaborative
• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.
  Curr Hematol Malig Rep Volume: 13 Page(s): 581 - 587
  12/01/2018 Authors: Pemmaraju N; Utengen A; Gupta V; Thompson MA; Lane AA
• Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms.
  Blood Volume: 132 Page(s): 2201 - 2205
  11/15/2018 Authors: Kennedy JA; Medeiros JJF; Dobson SM; Arruda A; Sukhai MA; Stockley T; Tierens A; Minden MD; Kamel-Reid S; Dick JE
• The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
  Blood Adv Volume: 2 Page(s): 2658 - 2671
  10/23/2018 Authors: McNamara CJ; Panzarella T; Kennedy JA; Arruda A; Claudio JO; Daher-Reyes G; Ho J; Siddiq N; Devlin R; Tsui H
• Body mass index and complications following major gastrointestinal surgery: a prospective, international cohort study and meta-analysis.
  Colorectal Dis Volume: 20 Page(s): O215 - O225
  08/01/2018 Authors: EuroSurg Collaborative
• Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice.
  Thromb Res Volume: 167 Page(s): 6 - 8
  07/01/2018 Authors: Duan A; Jackson Chornenki NL; Hillis CM; Gupta V; Anand SS; Siegal DM; Leong DP
• Identification of chronic obstructive pulmonary disease subgroups in 13 Asian cities.
  Int J Tuberc Lung Dis Volume: 22 Page(s): 820 - 826
  07/01/2018 Authors: Kim WJ; Gupta V; Nishimura M; Makita H; Idolor L; Roa C; Loh L-C; Ong C-K; Wang J-S; Boonsawat W
• Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
  Volume: 36
  05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK
• Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
  JAMA Oncol Volume: 4 Page(s): 652 - 659
  05/01/2018 Authors: Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T
• AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
  Leuk Res Volume: 68 Page(s): 22 - 28
  05/01/2018 Authors: Kavanagh S; Heath E; Hurren R; Gronda M; Barghout SH; Liyanage SU; Siriwardena TP; Claudio J; Zhang T; Sukhai M
• Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.
  Leukemia Volume: 32 Page(s): 1035 - 1038
  04/01/2018 Authors: Pardanani A; Gotlib J; Roberts AW; Wadleigh M; Sirhan S; Kawashima J; Maltzman JA; Shao L; Gupta V; Tefferi A
• Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
  Eur J Haematol Volume: 100 Page(s): 198 - 205
  02/01/2018 Authors: Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
• Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
  Leuk Lymphoma Volume: 59 Page(s): 237 - 240
  01/01/2018 Authors: Farshchi Zarabi S; Chan S; Gupta V; Khalaf D; Lutynski A; Minden MD; Rostom A; Rydlewski A; Schuh AC; Sibai H
• Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM.
  Curr Hematol Malig Rep Volume: 12 Page(s): 598 - 604
  12/01/2017 Authors: Pemmaraju N; Utengen A; Gupta V; Kiladjian J-J; Mesa R; Thompson MA
• Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN.
  Curr Hematol Malig Rep Volume: 12 Page(s): 592 - 597
  12/01/2017 Authors: Pemmaraju N; Utengen A; Gupta V; Thompson MA; Lane AA
• Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies.
  Hematol Oncol Stem Cell Ther Volume: 10 Page(s): 173 - 177
  12/01/2017 Authors: Chaudhri NA; Aljurf M; Almohareb FI; Alzahrani HA; Bashir Q; Savani B; Gupta V; Hashmi SK
• Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.
  Hematol Oncol Volume: 35 Page(s): 810 - 813
  12/01/2017 Authors: Deotare U; Shaheen M; Brandwein JM; Pitcher B; Kamel-Reid S; Yee KWL; Schimmer A; Minden MD; Gupta V; Schuh AC
• Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.
  Volume: 17 Page(s): 774 - 781
  11/01/2017 Authors: Bartoszko J; Panzarella T; McNamara CJ; Lau A; Schimmer AD; Schuh AC; Sibai H; Maze D; Yee KWL; Devlin R
• A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.
  Oncotarget Volume: 8 Page(s): 89256 - 89268
  10/24/2017 Authors: Williams BA; Law AD; Routy B; denHollander N; Gupta V; Wang X-H; Chaboureau A; Viswanathan S; Keating A
• Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
  J Hematol Oncol Volume: 10 Page(s): 156
  09/29/2017 Authors: Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian J-J; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A
• Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
  Blood Adv Volume: 1 Page(s): 1729 - 1738
  09/12/2017 Authors: Spiegel JY; McNamara C; Kennedy JA; Panzarella T; Arruda A; Stockley T; Sukhai M; Thomas M; Bartoszko J; Ho J
• Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1.
  Eur J Haematol Volume: 99 Page(s): 234 - 239
  09/01/2017 Authors: Bourlon C; Lipton JH; Deotare U; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Thyagu S; Messner HA; Michelis FV
• Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.
  Biol Blood Marrow Transplant Volume: 23 Page(s): 945 - 951
  06/01/2017 Authors: Michelis FV; Kotchetkov R; Grunwald RM; Azeem A; Atenafu EG; Lipton JH; Loach D; Gupta V; Kuruvilla J; Kim DD
• Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.
  Biol Blood Marrow Transplant Volume: 23 Page(s): 767 - 775
  05/01/2017 Authors: Liu HD; Ahn KW; Hu Z-H; Hamadani M; Nishihori T; Wirk B; Beitinjaneh A; Rizzieri D; Grunwald MR; Sabloff M
• Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.
  Ann Hematol Volume: 96 Page(s): 805 - 815
  05/01/2017 Authors: Moon JH; Hamad N; Sohn SK; Uhm J; Alam N; Gupta V; Lipton JH; Messner HA; Seftel M; Kuruvilla J
• Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
  Blood Volume: 129 Page(s): 1969 - 1979
  04/06/2017 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
• A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
  Haematologica Volume: 102 Page(s): 94 - 102
  01/01/2017 Authors: Gupta V; Mesa RA; Deininger MWN; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
• A 17-gene stemness score for rapid determination of risk in acute leukaemia.
  Nature Volume: 540 Page(s): 433 - 437
  12/15/2016 Authors: Ng SWK; Mitchell A; Kennedy JA; Chen WC; McLeod J; Ibrahimova N; Arruda A; Popescu A; Gupta V; Schimmer AD
• Myelofibrosis: to transplant or not to transplant?
  Hematology Am Soc Hematol Educ Program Volume: 2016 Page(s): 543 - 551
  12/02/2016 Authors: Devlin R; Gupta V
• Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.
  Biol Blood Marrow Transplant Volume: 22 Page(s): 2270 - 2275
  12/01/2016 Authors: Sibai H; Falcone U; Deotare U; Michelis FV; Uhm J; Gupta V; Kuruvilla J; Lipton JH; Seftel MD; Messner HA
• The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
  Haematologica Volume: 101 Page(s): e482 - e484
  12/01/2016 Authors: Gupta V; Harrison C; Hexner EO; Al-Ali HK; Foltz L; Montgomery M; Sun W; Gopalakrishna P; Kantarjian H; Verstovsek S
• Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM.
  Curr Hematol Malig Rep Volume: 11 Page(s): 456 - 461
  12/01/2016 Authors: Pemmaraju N; Utengen A; Gupta V; Kiladjian J-J; Mesa R; Thompson MA
• Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
  Curr Hematol Malig Rep Volume: 11 Page(s): 462 - 467
  12/01/2016 Authors: Pemmaraju N; Gupta V; Thompson MA; Lane AA
• The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes.
  Haematologica Volume: 101 Page(s): 1426 - 1433
  11/01/2016 Authors: Artz AS; Logan B; Zhu X; Akpek G; Bufarull RM; Gupta V; Lazarus HM; Litzow M; Loren A; Majhail NS
• A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.
  Cancer Med Volume: 5 Page(s): 3031 - 3040
  11/01/2016 Authors: Reed GA; Schiller GJ; Kambhampati S; Tallman MS; Douer D; Minden MD; Yee KW; Gupta V; Brandwein J; Jitkova Y
• Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.
  Am J Clin Pathol Volume: 146 Page(s): 408 - 422
  10/01/2016 Authors: Busque L; Porwit A; Day R; Olney HJ; Leber B; thier V; Sirhan S; Foltz L; Prchal J; Kamel-Reid S
• A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
  Invest New Drugs Volume: 34 Page(s): 614 - 624
  10/01/2016 Authors: Yee KWL; Chen H-WT; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T
• A phase I study of elesclomol sodium in patients with acute myeloid leukemia.
  Leuk Lymphoma Volume: 57 Page(s): 2437 - 2440
  10/01/2016 Authors: Hedley D; Shamas-Din A; Chow S; Sanfelice D; Schuh AC; Brandwein JM; Seftel MD; Gupta V; Yee KWL; Schimmer AD
• Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
  Haematologica Volume: 101 Page(s): 1065 - 1073
  09/01/2016 Authors: Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P
• Multicentre prospective cohort study of body mass index and postoperative complications following gastrointestinal surgery.
  Br J Surg Volume: 103 Page(s): 1157 - 1172
  08/01/2016 Authors: STARSurg Collaborative
• Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
  Volume: 17 Page(s): 769 - 777
  07/02/2016 Authors: Ponder KG; Matulis SM; Hitosugi S; Gupta VA; Sharp C; Burrows F; Nooka AK; Kaufman JL; Lonial S; Boise LH
• Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation.
  Volume: 51 Page(s): 841 - 847
  06/01/2016 Authors: Mayo S; Messner HA; Rourke SB; Howell D; Victor JC; Kuruvilla J; Lipton JH; Gupta V; Kim DD; Piescic C
• Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.
  Leukemia Volume: 30 Page(s): 1413 - 1415
  06/01/2016 Authors: Verstovsek S; Atallah E; Mascarenhas J; Sun H; Montgomery M; Gupta V; Mesa R; Gotlib J
• Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
  Volume: 34
  05/20/2016 Authors: Gupta V; Verstovsek S; Mesa RA; Gotlib JR; DiPersio JF; Catalano JV; Deininger MWN; Miller CB; Silver RT; Talpaz M
• Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.
  Biol Blood Marrow Transplant Volume: 22 Page(s): 932 - 940
  05/01/2016 Authors: Kumar R; Kimura F; Ahn KW; Hu Z-H; Kuwatsuka Y; Klein JP; Pasquini M; Miyamura K; Kato K; Yoshimi A
• Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
  Leukemia Volume: 30 Page(s): 1086 - 1093
  05/01/2016 Authors: Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
• Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy.
  Am J Hematol Volume: 91 Page(s): 283 - 286
  03/01/2016 Authors: Deotare U; Yee KWL; Le LW; Porwit A; Tierens A; Musani R; Barth D; Torlakovic E; Schimmer A; Schuh AC
• Outcomes of Allogeneic Hematopoietic Cell Transplantation inPatients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
  Biol Blood Marrow Transplant Volume: 22 Page(s): 432 - 440
  03/01/2016 Authors: Shanavas M; Popat U; Michaelis LC; Fauble V; McLornan D; Klisovic R; Mascarenhas J; Tamari R; Arcasoy MO; Davies J
• Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
  Curr Hematol Malig Rep Volume: 11 Page(s): 6 - 11
  02/01/2016 Authors: Viswabandya A; Devlin R; Gupta V
• Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.
  Curr Hematol Malig Rep Volume: 10 Page(s): 413 - 420
  12/01/2015 Authors: Pemmaraju N; Gupta V; Mesa R; Thompson MA
• Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
  Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 715 - 727
  12/01/2015 Authors: Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ
• Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.
  Bone Marrow Transplant Volume: 50 Page(s): 1405 - 1410
  11/01/2015 Authors: Michelis FV; Messner HA; Atenafu EG; McGillis L; Lambie A; Uhm J; Alam N; Seftel MD; Gupta V; Kuruvilla J
• Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis.
  Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): e151 - e156
  11/01/2015 Authors: Bartoszko J; Panzarella T; Lau A; Schimmer A; Schuh A; Shanavas M; Yee K; Gupta V
• Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
  Leukemia Volume: 29 Page(s): 2126 - 2133
  11/01/2015 Authors: Krger NM; Deeg JH; Olavarria E; Niederwieser D; Bacigalupo A; Barbui T; Rambaldi A; Mesa R; Tefferi A; Griesshammer M
• Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
  Biol Blood Marrow Transplant Volume: 21 Page(s): 1883 - 1887
  11/01/2015 Authors: Deeg HJ; Bredeson C; Farnia S; Ballen K; Gupta V; Mesa RA; Popat U; Hari P; Saber W; Seftel M
• Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.
  Biol Blood Marrow Transplant Volume: 21 Page(s): 1776 - 1782
  10/01/2015 Authors: Inamoto Y; Flowers MED; Wang T; Urbano-Ispizua A; Hemmer MT; Cutler CS; Couriel DR; Alousi AM; Antin JH; Gale RP
• A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
  Haematologica Volume: 100 Page(s): 1139 - 1145
  09/01/2015 Authors: Vannucchi AM; Kantarjian HM; Kiladjian J-J; Gotlib J; Cervantes F; Mesa RA; Sarlis NJ; Peng W; Sandor V; Gopalakrishna P
• Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.
  Bone Marrow Transplant Volume: 50 Page(s): 1180 - 1186
  09/01/2015 Authors: Alam N; Atenafu EG; Kuruvilla J; Uhm J; Lipton JH; Messner HA; Kim DH; Seftel M; Gupta V
• Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age.
  J Geriatr Oncol Volume: 6 Page(s): 262 - 271
  07/01/2015 Authors: Alibhai SMH; Breunis H; Timilshina N; Brignardello-Petersen R; Tomlinson G; Mohamedali H; Gupta V; Minden MD; Li M; Buckstein R
• Mixed fields on RhD typing as an indication of loss of heterozygosity on chromosome 1p in acute myeloid leukemia.
  Leuk Lymphoma Volume: 56 Page(s): 2196 - 2199
  07/01/2015 Authors: Chow S; Pendergrast J; Ochoa-Garay G; Gupta V; Munir ME; Craddock KJ; Wei C; Kamel-Reid S; Cserti-Gazdewich CM
• Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.
  Bone Marrow Transplant Volume: 50 Page(s): 907 - 913
  07/01/2015 Authors: Michelis FV; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Lipton JH; Loach D; Seftel MD; Uhm J; Alam N
• Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD.
  Bone Marrow Transplant Volume: 50 Page(s): 734 - 742
  05/01/2015 Authors: Alam N; Xu W; Atenafu EG; Uhm J; Seftel M; Gupta V; Kuruvilla J; Lipton JH; Messner HA; Kim DDH
• Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
  Bone Marrow Transplant Volume: 50 Page(s): 628 - 636
  05/01/2015 Authors: Tamari R; Mughal TI; Rondelli D; Hasserjian R; Gupta V; Odenike O; Fauble V; Finazzi G; Pane F; Mascarenhas J
• Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
  Am J Hematol Volume: 90 Page(s): 392 - 399
  05/01/2015 Authors: Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DDH
• Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.
  Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): e73 - e81
  05/01/2015 Authors: Michelis FV; Messner HA; Uhm J; Alam N; Lambie A; McGillis L; Seftel MD; Gupta V; Kuruvilla J; Lipton JH
• Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
  Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 214 - 221.e1
  04/01/2015 Authors: Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
• A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis.
  Br J Haematol Volume: 168 Page(s): 384 - 394
  02/01/2015 Authors: Kuo KHM; Callum JL; Panzarella T; Jacks LM; Brandwein J; Crump M; Curtis JE; Gupta V; Lipton JH; Minden MD
• How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
  Eur J Haematol Volume: 94 Page(s): 115 - 119
  02/01/2015 Authors: Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
• A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
  Leuk Lymphoma Volume: 56 Page(s): 2793 - 2802
  01/01/2015 Authors: How J; Minden MD; Brian L; Chen EX; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Webster S; Degelder T
• Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.
  Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): e1 - e5
  01/01/2015 Authors: Yan M; Geyer H; Mesa R; Atallah E; Callum J; Bartoszko J; Yee K; Maganti M; Wong F; Gupta V
• Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis.
  PLoS One Volume: 10 Page(s): e0123171
  01/01/2015 Authors: Camargo JF; Bhimji A; Kumar D; Kaul R; Pavan R; Schuh A; Seftel M; Lipton JH; Gupta V; Humar A
• The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.
  Volume: 49 Page(s): 1528 - 1534
  12/01/2014 Authors: Uhm J; Hamad N; Michelis FV; Shanavas M; Kuruvilla J; Gupta V; Lipton JH; Messner HA; Seftel M; Kim DD
• Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
  Biol Blood Marrow Transplant Volume: 20 Page(s): 1751 - 1757
  11/01/2014 Authors: Uhm J; Hamad N; Shin EM; Michelis FV; Shanavas M; Gupta V; Kuruvilla J; Lipton JH; Messner HA; Seftel M
• Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning.
  Biol Blood Marrow Transplant Volume: 20 Page(s): 1722 - 1728
  11/01/2014 Authors: Hamad N; Del Bel R; Messner HA; Kim D; Kuruvilla J; Lipton JH; Uhm J; Seftel M; Alam N; Xu W
• Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.
  Leuk Lymphoma Volume: 55 Page(s): 2398 - 2401
  10/01/2014 Authors: Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DDH; Uhm J; Lambie A; Ellis L
• Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts.
  Eur J Haematol Volume: 93 Page(s): 273 - 280
  10/01/2014 Authors: Michelis FV; Messner HA; Loach D; Uhm J; Gupta V; Lipton JH; Seftel MD; Kuruvilla J; Kim DD
• Transcriptional and Post-translational Regulation of the BcI-2 Family by IL-6 Mediates Resistance to ABT-737 in Multiple Myeloma
  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S148 - S148
  09/01/2014 Authors: Gupta VA; Matulis SM; Nooka AK; Kaufman JL; Lonial S; Boise LH
• Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning.
  Bone Marrow Transplant Volume: 49 Page(s): 1162 - 1169
  09/01/2014 Authors: Shanavas M; Messner HA; Atenafu EG; Kim DH; Kuruvilla J; Lipton JH; Uhm J; Seftel M; Alam N; Gupta V
• Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
  Biol Blood Marrow Transplant Volume: 20 Page(s): 1274 - 1281
  09/01/2014 Authors: Gupta V; Gotlib J; Radich JP; Krger NM; Rondelli D; Verstovsek S; Deeg HJ
• Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.
  Br J Haematol Volume: 166 Page(s): 303 - 306
  07/01/2014 Authors: Yee KWL; Brandwein J; Schimmer AD; Gupta V; Del Bel R; Xu W; Minden MD; Schuh AC
• Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
  Best Pract Res Clin Haematol Volume: 27 Page(s): 165 - 174
  06/01/2014 Authors: Shanavas M; Gupta V
• Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.
  Leuk Res Volume: 38 Page(s): 532 - 536
  05/01/2014 Authors: Brandwein JM; Atenafu EG; Schuh AC; Yee KWL; Schimmer AD; Gupta V; Minden MD
• Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models.
  Bone Marrow Transplant Volume: 49 Page(s): 649 - 656
  05/01/2014 Authors: Kim D; Won H-H; Su S; Cheng L; Xu W; Hamad N; Uhm J; Gupta V; Kuruvilla J; Messner HA
• Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?
  Ann Oncol Volume: 25 Page(s): 883 - 888
  04/01/2014 Authors: Timilshina N; Breunis H; Brandwein JM; Minden MD; Gupta V; O'Neill S; Tomlinson GA; Buckstein R; Li M; Alibhai SMH
• Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
  Am J Hematol Volume: 89 Page(s): 363 - 368
  04/01/2014 Authors: Minden MD; Hogge DE; Weir SJ; Kasper J; Webster DA; Patton L; Jitkova Y; Hurren R; Gronda M; Goard CA
• Benefit of allogeneic transplantation in patients age 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
  Biol Blood Marrow Transplant Volume: 20 Page(s): 474 - 479
  04/01/2014 Authors: Michelis FV; Messner HA; Atenafu EG; Kim DD; Kuruvilla J; Lipton JH; Uhm J; Loach D; Gupta V
• Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
  Biol Blood Marrow Transplant Volume: 20 Page(s): 556 - 563
  04/01/2014 Authors: Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J
• Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
  Nature Volume: 506 Page(s): 328 - 333
  02/20/2014 Authors: Shlush LI; Zandi S; Mitchell A; Chen WC; Brandwein JM; Gupta V; Kennedy JA; Schimmer AD; Schuh AC; Yee KW
• A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
  Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): 87 - 92
  02/01/2014 Authors: Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DDH; Uhm J; Lambie A; Ellis L
• Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma
  Volume: 122
  11/15/2013 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
• P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma
  Volume: 122
  11/15/2013 Authors: Shah SP; Gupta VA; Matulis SM; Nooka AK; Lonial S; Boise LH
• Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma
  Volume: 122
  11/15/2013 Authors: Rossi MR; Newman S; Nooka AK; Kaufman JL; Bahlis NJ; Neri P; Matulis SM; Bernal-Mizrachi L; Gupta VA; Varma A
• Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.
  Bone Marrow Transplant Volume: 48 Page(s): 1450 - 1455
  11/01/2013 Authors: Michelis FV; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Lambie A; Lipton JH; Loach D; Messner HA
• Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol.
  Br J Haematol Volume: 163 Page(s): 458 - 464
  11/01/2013 Authors: Martell MP; Atenafu EG; Minden MD; Schuh AC; Yee KWL; Schimmer AD; Gupta V; Brandwein JM
• Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT.
  Bone Marrow Transplant Volume: 48 Page(s): 1104 - 1111
  08/01/2013 Authors: Kim D; Al-Dawsari G; Chang H; Panzarella T; Gupta V; Kuruvilla J; Lipton JH; Messner HA
• Response: chemotherapy versus allogeneic transplantation in adult patients with acute lymphoblastic leukemia in first remission--not a time for dogma.
  Blood Volume: 121 Page(s): 5255
  06/27/2013 Authors: Gupta V; Richards S; Rowe JM
• Effects of spleen status on early outcomes after hematopoietic cell transplantation.
  Bone Marrow Transplant Volume: 48 Page(s): 825 - 831
  06/01/2013 Authors: Akpek G; Pasquini MC; Logan B; Agovi M-A; Lazarus HM; Marks DI; Bornhaeser M; Ringdn O; Maziarz RT; Gupta V
• High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.
  Leuk Res Volume: 37 Page(s): 556 - 560
  05/01/2013 Authors: Hassanein M; Atenafu EG; Schuh AC; Yee KWL; Minden MD; Schimmer AD; Gupta V; Brandwein JM
• Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.
  Blood Volume: 121 Page(s): 2725 - 2733
  04/04/2013 Authors: Kennedy JA; Atenafu EG; Messner HA; Craddock KJ; Brandwein JM; Lipton JH; Minden MD; Schimmer AD; Schuh AC; Yee KW
• Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research.
  Haematologica Volume: 98 Page(s): 185 - 192
  02/01/2013 Authors: Keating A; DaSilva G; Prez WS; Gupta V; Cutler CS; Ballen KK; Cairo MS; Camitta BM; Champlin RE; Gajewski JL
• Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis.
  Blood Volume: 121 Page(s): 339 - 350
  01/10/2013 Authors: Gupta V; Richards S; Rowe J; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group
• Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
  Clin Transplant Volume: 27 Page(s): 930 - 937
  01/01/2013 Authors: Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
• Polycythemia vera followed by hairy cell leukemia variant.
  Blood Volume: 120 Page(s): 5100
  12/20/2012 Authors: Kotchetkov R; Gupta V
• Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
  Cancer Volume: 118 Page(s): 6110 - 6117
  12/15/2012 Authors: How J; Sykes J; Gupta V; Yee KWL; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
• Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation.
  Biol Blood Marrow Transplant Volume: 18 Page(s): 1905 - 1910
  12/01/2012 Authors: Alam N; Marras TK; Atenafu EG; Gupta V; Kuruvilla J; Lipton JH; Messner HA; Kim DDH
• Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen.
  Leuk Res Volume: 36 Page(s): 1517 - 1520
  12/01/2012 Authors: Liew E; Atenafu EG; Schimmer AD; Yee KWL; Schuh AC; Minden MD; Gupta V; Brandwein JM
• Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
  Volume: 120
  11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH
• Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
  Expert Opin Pharmacother Volume: 13 Page(s): 2397 - 2407
  11/01/2012 Authors: Vaddi K; Sarlis NJ; Gupta V
• Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia.
  Leuk Res Volume: 36 Page(s): 1241 - 1248
  10/01/2012 Authors: Mohamedali H; Breunis H; Timilshina N; Brandwein JM; Gupta V; Minden MD; Li M; Tomlinson G; Buckstein R; Alibhai SMH
• Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
  Biol Blood Marrow Transplant Volume: 18 Page(s): 1589 - 1599
  10/01/2012 Authors: Wong KM; Atenafu EG; Kim D; Kuruvilla J; Lipton JH; Messner H; Gupta V
• No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation.
  Transpl Infect Dis Volume: 14 Page(s): 468 - 478
  10/01/2012 Authors: Tomblyn M; Chen M; Kukreja M; Aljurf MD; Al Mohareb F; Bolwell BJ; Cahn J-Y; Carabasi MH; Gale RP; Gress RE
• A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies.
  Clin Lymphoma Myeloma Leuk Volume: 12 Page(s): 330 - 336
  10/01/2012 Authors: Schimmer AD; Jitkova Y; Gronda M; Wang Z; Brandwein J; Chen C; Gupta V; Schuh A; Yee K; Chen J
• HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival.
  Biol Blood Marrow Transplant Volume: 18 Page(s): 1401 - 1406
  09/01/2012 Authors: Battiwalla M; Wang T; Carreras J; Deeg HJ; Ayas M; Bajwa RPS; George B; Gupta V; Pasquini R; Schrezenmeier H
• Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
  Blood Volume: 120 Page(s): 1367 - 1379
  08/16/2012 Authors: Gupta V; Hari P; Hoffman R
• Tolerance to liver allograft after allogeneic hematopoietic cell transplantation for severe aplastic anemia from the same HLA-matched sibling donor.
  Bone Marrow Transplant Volume: 47 Page(s): 1128 - 1130
  08/01/2012 Authors: Sun H; Therapondos G; Lipton J; Gupta V
• Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.
  Br J Haematol Volume: 158 Page(s): 506 - 514
  08/01/2012 Authors: Thyagu S; Minden MD; Gupta V; Yee KWL; Schimmer AD; Schuh AC; Lipton JH; Messner HA; Xu W; Brandwein JM
• Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.
  Volume: 30
  05/20/2012 Authors: Verstovsek S; Mesa RA; Gotlib JR; Gupta V; DiPersio JF; Catalano JV; Deininger MWN; Miller CB; Silver RT; Talpaz M
• Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
  Am J Hematol Volume: 87 Page(s): 562 - 568
  05/01/2012 Authors: Abdel-Wahab O; Pardanani A; Bernard OA; Finazzi G; Crispino JD; Gisslinger H; Kralovics R; Odenike O; Bhalla K; Gupta V
• RBC-transfusion guidelines update.
  Leuk Res Volume: 36 Page(s): 659 - 660
  05/01/2012 Authors: Gale RP; Barosi G; Barbui T; Cervantes F; Dohner K; Dupriez B; Gupta V; Harrison C; Hoffman R; Kiladjian JJ
• Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
  Am J Hematol Volume: 87 Page(s): 323 - 326
  03/01/2012 Authors: Saini L; Minden MD; Schuh AC; Yee KWL; Schimmer AD; Gupta V; Atenafu EG; Murray C; Nixon S; Brandwein JM
• A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning.
  Biol Blood Marrow Transplant Volume: 18 Page(s): 113 - 124
  01/01/2012 Authors: Gupta V; Panzarella T; Li L; Khan J; Sharma A; Lipton JH; Kuruvilla J; Messner H; Alibhai SMH
• Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
  Blood Volume: 118 Page(s): 2351 - 2357
  08/25/2011 Authors: Marsh JC; Gupta V; Lim Z; Ho AY; Ireland RM; Hayden J; Potter V; Koh MB; Islam MS; Russell N
• A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.
  Leukemia Volume: 25 Page(s): 945 - 952
  06/01/2011 Authors: Brandwein JM; Hedley DW; Chow S; Schimmer AD; Yee KWL; Schuh AC; Gupta V; Xu W; Kamel-Reid S; Minden MD
• Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia.
  Biol Blood Marrow Transplant Volume: 17 Page(s): 737 - 744
  05/01/2011 Authors: Barker CC; Agovi M-A; Logan B; Lazarus HM; Ballen KK; Gupta V; Hale GA; Frangoul H; Ho V; Rizzo JD
• Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.
  Bone Marrow Transplant Volume: 46 Page(s): 516 - 522
  04/01/2011 Authors: Khabori MA; El-Emary M; Xu W; Guyatt G; Galal A; Kuruvilla J; Lipton J; Messner H; Gupta V
• Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns.
  Blood Volume: 117 Page(s): 2307 - 2318
  02/24/2011 Authors: Gupta V; Tallman MS; Weisdorf DJ
• Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).
  Biol Blood Marrow Transplant Volume: 17 Page(s): 157 - 166
  02/01/2011 Authors: Loren AW; Chow E; Jacobsohn DA; Gilleece M; Halter J; Joshi S; Wang Z; Sobocinski KA; Gupta V; Hale GA
• What are RBC-transfusion-dependence and -independence?
  Leuk Res Volume: 35 Page(s): 8 - 11
  01/01/2011 Authors: Gale RP; Barosi G; Barbui T; Cervantes F; Dohner K; Dupriez B; Gupta V; Harrison C; Hoffman R; Kiladjian J-J
• Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors.
  Haematologica Volume: 95 Page(s): 2119 - 2125
  12/01/2010 Authors: Gupta V; Eapen M; Brazauskas R; Carreras J; Aljurf M; Gale RP; Hale GA; Ilhan O; Passweg JR; Ringdn O
• Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.
  Biol Blood Marrow Transplant Volume: 16 Page(s): 1442 - 1450
  10/01/2010 Authors: Navarro WH; Agovi M-A; Logan BR; Ballen K; Bolwell BJ; Frangoul H; Gupta V; Hahn T; Ho VT; Juckett M
• Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
  J Clin Oncol Volume: 28 Page(s): 3730 - 3738
  08/10/2010 Authors: Duval M; Klein JP; He W; Cahn J-Y; Cairo M; Camitta BM; Kamble R; Copelan E; de Lima M; Gupta V
• Second unrelated donor hematopoietic cell transplantation for primary graft failure.
  Biol Blood Marrow Transplant Volume: 16 Page(s): 1099 - 1106
  08/01/2010 Authors: Schriber J; Agovi M-A; Ho V; Ballen KK; Bacigalupo A; Lazarus HM; Bredeson CN; Gupta V; Maziarz RT; Hale GA
• Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR.
  Bone Marrow Transplant Volume: 45 Page(s): 1256 - 1258
  07/01/2010 Authors: Kohli R; Xu W; Brandwein J; Minden MD; Schimmer A; Schuh AC; Lipton JH; Yee K; Messner HA; Gupta V
• Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes.
  Bone Marrow Transplant Volume: 45 Page(s): 877 - 885
  05/01/2010 Authors: Armand P; Deeg HJ; Kim HT; Lee H; Armistead P; de Lima M; Gupta V; Soiffer RJ
• Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.
  Biol Blood Marrow Transplant Volume: 16 Page(s): 543 - 547
  04/01/2010 Authors: Kalaycio ME; Kukreja M; Woolfrey AE; Szer J; Cortes J; Maziarz RT; Bolwell BJ; Buser A; Copelan E; Gale RP
• Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.
  Br J Haematol Volume: 148 Page(s): 791 - 796
  03/01/2010 Authors: Risitano AM; Selleri C; Serio B; Torelli GF; Kulagin A; Maury S; Halter J; Gupta V; Bacigalupo A; Soci G
• Outcome of transplantation for myelofibrosis.
  Biol Blood Marrow Transplant Volume: 16 Page(s): 358 - 367
  03/01/2010 Authors: Ballen KK; Shrestha S; Sobocinski KA; Zhang M-J; Bashey A; Bolwell BJ; Cervantes F; Devine SM; Gale RP; Gupta V
• Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia.
  Leuk Lymphoma Volume: 51 Page(s): 61 - 65
  01/01/2010 Authors: Al-Khabori M; Minden MD; Yee KWL; Gupta V; Schimmer AD; Schuh AC; Xu W; Brandwein JM
• The effect of smoking on allogeneic transplant outcomes.
  Biol Blood Marrow Transplant Volume: 15 Page(s): 1277 - 1287
  10/01/2009 Authors: Marks DI; Ballen K; Logan BR; Wang Z; Sobocinski KA; Bacigalupo A; Burns LJ; Gupta V; Ho V; McCarthy PL
• A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
  Bone Marrow Transplant Volume: 44 Page(s): 317 - 320
  09/01/2009 Authors: Gupta V; Krger N; Aschan J; Xu W; Leber B; Dalley C; Sabloff M; Lipton JH; Messner H; Brune M
• Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.
  Br J Haematol Volume: 146 Page(s): 76 - 85
  06/01/2009 Authors: Storring JM; Minden MD; Kao S; Gupta V; Schuh AC; Schimmer AD; Yee KWL; Kamel-Reid S; Chang H; Lipton JH
• Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.
  Biol Blood Marrow Transplant Volume: 15 Page(s): 471 - 482
  04/01/2009 Authors: Kim DH; Popradi G; Xu W; Gupta V; Kuruvilla J; Wright J; Messner HA; Lipton JH
• Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia.
  Crit Rev Oncol Hematol Volume: 69 Page(s): 168 - 174
  02/01/2009 Authors: Alibhai SMH; Leach M; Gupta V; Tomlinson GA; Brandwein JM; Saiz FS; Minden MD
• Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
  Biol Blood Marrow Transplant Volume: 15 Page(s): 109 - 117
  01/01/2009 Authors: Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA
• Acute lung injury during antithymocyte globulin therapy for aplastic anemia.
  Can Respir J Volume: 16 Page(s): e3 - e5
  01/01/2009 Authors: Goligher EC; Cserti-Gazdewich C; Balter M; Gupta V; Brandwein JE
• A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
  Clin Cancer Res Volume: 14 Page(s): 8295 - 8301
  12/15/2008 Authors: Schimmer AD; O'Brien S; Kantarjian H; Brandwein J; Cheson BD; Minden MD; Yee K; Ravandi F; Giles F; Schuh A
• Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy.
  Br J Haematol Volume: 143 Page(s): 738 - 743
  12/01/2008 Authors: Kao SY; Xu W; Brandwein JM; Lipton JH; Messner HA; Minden MD; Schimmer AD; Schuh AC; Yee K; Gupta V
• B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency.
  J Exp Med Volume: 205 Page(s): 2755 - 2761
  11/24/2008 Authors: Gupta VA; Hermiston ML; Cassafer G; Daikh DI; Weiss A
• B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and fas deficiency
  Volume: 58 Page(s): S443 - S444
  09/01/2008 Authors: Gupta VA; Hermiston ML; Cassafer G; Daikh DI; Weiss A
• Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies.
  Bone Marrow Transplant Volume: 42 Page(s): 51 - 56
  07/01/2008 Authors: Siegal D; Xu W; Sutherland R; Kamel-Reid S; Kuruvilla J; Lipton JH; Minden M; Messner H; Gupta V
• Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
  Biol Blood Marrow Transplant Volume: 14 Page(s): 775 - 782
  07/01/2008 Authors: Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
• Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
  Transpl Infect Dis Volume: 10 Page(s): 90 - 98
  04/01/2008 Authors: Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
• Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
  Cancer Volume: 112 Page(s): 1513 - 1521
  04/01/2008 Authors: Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A
• Alternative donor transplants for high-risk acute myeloid leukemia.
  Curr Opin Hematol Volume: 15 Page(s): 115 - 120
  03/01/2008 Authors: Gupta V
• Superstition but not distrust in the medical system predicts the use of complementary and alternative medicine in a group of patients with acute leukemia.
  Leuk Lymphoma Volume: 49 Page(s): 339 - 341
  02/01/2008 Authors: Lourenco MT; Walsh A; Boon H; Al-Khabouri M; Brandwein J; Gupta V; Schuh A; Yee K; Rodin G; Schimmer AD
• Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy.
  Am J Hematol Volume: 83 Page(s): 54 - 58
  01/01/2008 Authors: Brandwein JM; Gupta V; Schuh AC; Schimmer AD; Yee K; Xu W; Messner HA; Lipton JH; Minden MD
• Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
  Clin Transplant Volume: 22 Page(s): 770 - 779
  01/01/2008 Authors: Kim DH; Kumar D; Messner HA; Minden M; Gupta V; Kuruvilla J; Chae YS; Sohn SK; Lipton JH
• Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance.
  Biol Blood Marrow Transplant Volume: 13 Page(s): 1369 - 1379
  11/01/2007 Authors: Siegal D; Keller A; Xu W; Bhuta S; Kim DH; Kuruvilla J; Lipton JH; Messner H; Gupta V
• Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.
  Bone Marrow Transplant Volume: 40 Page(s): 913 - 914
  11/01/2007 Authors: Amarasinghe K; Dalley C; Dokal I; Laurie A; Gupta V; Marsh J
• The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults.
  Crit Rev Oncol Hematol Volume: 64 Page(s): 19 - 30
  10/01/2007 Authors: Alibhai SMH; Leach M; Kermalli H; Gupta V; Kowgier ME; Tomlinson GA; Brandwein J; Buckstein R; Minden MD
• Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts.
  Biol Blood Marrow Transplant Volume: 13 Page(s): 1233 - 1243
  10/01/2007 Authors: Kim DH; Jamal N; Saragosa R; Loach D; Wright J; Gupta V; Kuruvilla J; Lipton JH; Minden M; Messner HA
• Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience.
  Bone Marrow Transplant Volume: 40 Page(s): 369 - 372
  08/01/2007 Authors: Stakiw J; Kim DH; Kuruvilla J; Gupta V; Messner H; Lipton JH
• Acute promyelocytic leukemia in patients aged 70 years and over -- a single center experience of unselected patients.
  Leuk Lymphoma Volume: 48 Page(s): 1654 - 1658
  08/01/2007 Authors: Disperati P; Minden MD; Gupta V; Schimmer AD; Schuh AC; Yee KWL; Kamel-Reid S; Chang H; Xu W; Brandwein JM
• The outcome of intensive induction therapy in patients >or=70 years with acute myeloid leukemia.
  Leukemia Volume: 21 Page(s): 1321 - 1324
  06/01/2007 Authors: Gupta V; Xu W; Keng C; Alibhai SMH; Brandwein J; Schimmer A; Schuh A; Yee K; Minden MD
• A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response.
  Leukemia Volume: 21 Page(s): 821 - 824
  04/01/2007 Authors: Brandwein JM; Yang L; Schimmer AD; Schuh AC; Gupta V; Wells RA; Alibhai SMH; Xu W; Minden MD
• Marrow transplantation for severe aplastic anemia with significant renal impairment.
  Bone Marrow Transplant Volume: 39 Page(s): 311 - 313
  03/01/2007 Authors: Gerrie A; Marsh J; Lipton JH; Messner H; Gupta V
• Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).
  Leuk Lymphoma Volume: 48 Page(s): 65 - 71
  01/01/2007 Authors: Medeiros BC; Minden MD; Schuh AC; Schimmer AD; Yee K; Lipton JH; Messner HA; Gupta V; Chun K; Xu W
• Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults.
  Br J Haematol Volume: 134 Page(s): 95 - 99
  07/01/2006 Authors: Gupta V; Brooker C; Tooze JA; Yi Q-L; Sage D; Turner D; Kangasabapathy P; Marsh JCW
• The juxtamembrane wedge negatively regulates CD45 function in B cells.
  Immunity Volume: 23 Page(s): 635 - 647
  12/01/2005 Authors: Hermiston ML; Tan AL; Gupta VA; Majeti R; Weiss A
• Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
  Leuk Res Volume: 29 Page(s): 1381 - 1386
  12/01/2005 Authors: Brandwein JM; Gupta V; Wells RA; Schuh AC; Schimmer AD; Lipton JH; Messner HA; Yi Q-L; Chun K; Kamel-Reid S
• Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
  Biol Blood Marrow Transplant Volume: 11 Page(s): 764 - 772
  10/01/2005 Authors: Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi Q-L; Minden M; Messner H
• A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells.
  Mol Cell Biol Volume: 25 Page(s): 4426 - 4441
  06/01/2005 Authors: Roose JP; Mollenauer M; Gupta VA; Stone J; Weiss A
• Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
  Cancer Volume: 103 Page(s): 2082 - 2090
  05/15/2005 Authors: Gupta V; Chun K; Yi Q-L; Minden M; Schuh A; Wells R; Brandwein J
• A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders.
  Br J Haematol Volume: 129 Page(s): 110 - 117
  04/01/2005 Authors: Gupta V; Gordon-Smith EC; Cook G; Parker A; Duguid JKM; Wilson KMO; Yi Q-L; Marsh JCW
• Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
  Bone Marrow Transplant Volume: 35 Page(s): 467 - 471
  03/01/2005 Authors: Gupta V; Ball SE; Sage D; Ortin M; Freires M; Gordon-Smith EC; Marsh JCW
• Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
  Leuk Res Volume: 29 Page(s): 113 - 114
  01/01/2005 Authors: Gupta V; Yi Q-L; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
• Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
  Biol Blood Marrow Transplant Volume: 10 Page(s): 867 - 876
  12/01/2004 Authors: Gupta V; Ball SE; Yi Q-L; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H
• Cavernous sinus thrombosis presenting with diplopia in an allogeneic bone marrow transplant recipient.
  Am J Hematol Volume: 77 Page(s): 77 - 81
  09/01/2004 Authors: Gupta V; Keller A; Halliday W; Sanche S; Hassegawa W; Messner H; Kiss T; Lipton J
• Trisomy 4 as the sole cytogenetic abnormality in a patient with T-cell acute lymphoblastic leukemia.
  Cancer Genet Cytogenet Volume: 152 Page(s): 158 - 162
  07/15/2004 Authors: Gupta V; Chun K
• Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.
  Bone Marrow Transplant Volume: 33 Page(s): 1201 - 1208
  06/01/2004 Authors: Mollee P; Gupta V; Song K; Reddy V; Califaretti N; Tsang R; Crump M; Keating A
• Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.
  Leuk Lymphoma Volume: 45 Page(s): 469 - 480
  03/01/2004 Authors: Gupta V; Yib Q-L; Brandwein J; Chun K; Lipton JH; Messner H; Schuh AC; Wells RA; Minden MD; Kamel-Reidc S
• The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison.
  Bone Marrow Transplant Volume: 33 Page(s): 397 - 404
  02/01/2004 Authors: Gupta V; Yi Q-L; Brandwein J; Minden MD; Schuh AC; Wells RA; Chun K; Kamel-Reid S; Tsang R; Daly A
• Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia.
  Leuk Res Volume: 27 Page(s): 983 - 991
  11/01/2003 Authors: Gupta V; Minden MD; Yi Q-L; Brandwein J; Chun K
• Myeloablative conditioning regimens for AML allografts: 30 years later.
  Bone Marrow Transplant Volume: 32 Page(s): 969 - 978
  11/01/2003 Authors: Gupta V; Lazarus HM; Keating A
• Vascular events associated with alpha interferon therapy.
  Leuk Lymphoma Volume: 44 Page(s): 471 - 475
  03/01/2003 Authors: Al-Zahrani H; Gupta V; Minden MD; Messner HA; Lipton JH
• Association of familial leukemia with HLA Cw3: is it real?
  Leuk Lymphoma Volume: 44 Page(s): 309 - 311
  02/01/2003 Authors: Kuruvilla J; Gupta V; Gill KS; Lipton JH
• The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling.
  Dev Cell Volume: 1 Page(s): 63 - 72
  07/01/2001 Authors: Shaw RJ; Paez JG; Curto M; Yaktine A; Pruitt WM; Saotome I; O'Bryan JP; Gupta V; Ratner N; Der CJ